| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 18 | 2024 | 146 | 5.790 |
Why?
|
| Deep Brain Stimulation | 11 | 2024 | 62 | 5.410 |
Why?
|
| Supranuclear Palsy, Progressive | 10 | 2022 | 21 | 3.460 |
Why?
|
| Subthalamic Nucleus | 6 | 2018 | 23 | 2.710 |
Why?
|
| Parkinsonian Disorders | 5 | 2019 | 21 | 1.480 |
Why?
|
| Gait | 3 | 2015 | 81 | 1.370 |
Why?
|
| Deglutition Disorders | 2 | 2022 | 119 | 1.320 |
Why?
|
| Gait Disorders, Neurologic | 3 | 2019 | 16 | 1.200 |
Why?
|
| Deglutition | 2 | 2015 | 76 | 0.970 |
Why?
|
| Globus Pallidus | 1 | 2024 | 19 | 0.940 |
Why?
|
| Movement Disorders | 1 | 2022 | 44 | 0.840 |
Why?
|
| Essential Tremor | 1 | 2020 | 6 | 0.740 |
Why?
|
| Implantable Neurostimulators | 1 | 2020 | 12 | 0.740 |
Why?
|
| Spinocerebellar Ataxias | 2 | 2024 | 76 | 0.730 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2020 | 51 | 0.720 |
Why?
|
| Brain | 10 | 2024 | 2281 | 0.720 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2020 | 202 | 0.680 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 124 | 0.680 |
Why?
|
| Disease Progression | 6 | 2024 | 1488 | 0.660 |
Why?
|
| Health Status Disparities | 1 | 2021 | 187 | 0.650 |
Why?
|
| Defibrillators, Implantable | 1 | 2020 | 142 | 0.650 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 3 | 2016 | 36 | 0.640 |
Why?
|
| Antiparkinson Agents | 3 | 2013 | 15 | 0.600 |
Why?
|
| Cardiomyopathies | 1 | 2020 | 264 | 0.600 |
Why?
|
| Tremor | 2 | 2019 | 22 | 0.570 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 410 | 0.540 |
Why?
|
| Ataxia | 2 | 2014 | 39 | 0.520 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 2015 | 19 | 0.510 |
Why?
|
| Humans | 49 | 2024 | 89063 | 0.510 |
Why?
|
| Aged | 21 | 2024 | 19077 | 0.500 |
Why?
|
| Male | 30 | 2024 | 42251 | 0.490 |
Why?
|
| tau Proteins | 3 | 2019 | 74 | 0.490 |
Why?
|
| Catechol O-Methyltransferase | 6 | 2003 | 69 | 0.480 |
Why?
|
| Chorea | 1 | 2014 | 12 | 0.470 |
Why?
|
| Methamphetamine | 4 | 2004 | 85 | 0.450 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2014 | 109 | 0.440 |
Why?
|
| Nortropanes | 1 | 2012 | 10 | 0.420 |
Why?
|
| Dopamine Agonists | 1 | 2012 | 27 | 0.420 |
Why?
|
| Severity of Illness Index | 5 | 2019 | 1837 | 0.420 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2012 | 94 | 0.410 |
Why?
|
| Fragile X Syndrome | 1 | 2012 | 16 | 0.400 |
Why?
|
| Iodine Radioisotopes | 1 | 2012 | 134 | 0.400 |
Why?
|
| Nerve Tissue Proteins | 4 | 2022 | 511 | 0.390 |
Why?
|
| Multiple System Atrophy | 2 | 2022 | 4 | 0.390 |
Why?
|
| Middle Aged | 18 | 2024 | 25863 | 0.370 |
Why?
|
| Melatonin | 2 | 2021 | 50 | 0.370 |
Why?
|
| Neurons | 4 | 2004 | 1580 | 0.360 |
Why?
|
| Biomarkers | 5 | 2019 | 1755 | 0.360 |
Why?
|
| Disease Management | 1 | 2012 | 329 | 0.350 |
Why?
|
| Female | 25 | 2024 | 46011 | 0.340 |
Why?
|
| Interdisciplinary Research | 1 | 2019 | 6 | 0.340 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2012 | 257 | 0.340 |
Why?
|
| Double-Blind Method | 5 | 2019 | 1714 | 0.340 |
Why?
|
| Treatment Outcome | 8 | 2019 | 8203 | 0.340 |
Why?
|
| Membrane Glycoproteins | 2 | 2002 | 432 | 0.330 |
Why?
|
| Basal Ganglia Diseases | 1 | 2018 | 9 | 0.320 |
Why?
|
| Dopamine | 4 | 2004 | 276 | 0.310 |
Why?
|
| Neurofilament Proteins | 1 | 2017 | 14 | 0.310 |
Why?
|
| Neurodegenerative Diseases | 1 | 2018 | 51 | 0.300 |
Why?
|
| Global Health | 1 | 2019 | 186 | 0.300 |
Why?
|
| Oligopeptides | 2 | 2017 | 188 | 0.290 |
Why?
|
| Machine Learning | 2 | 2019 | 257 | 0.280 |
Why?
|
| Dystonia | 1 | 2017 | 29 | 0.280 |
Why?
|
| Basal Ganglia | 1 | 2016 | 46 | 0.270 |
Why?
|
| Drug Utilization | 1 | 2017 | 65 | 0.270 |
Why?
|
| Germany | 3 | 2020 | 72 | 0.270 |
Why?
|
| Wallerian Degeneration | 1 | 2006 | 3 | 0.270 |
Why?
|
| Neurotoxins | 1 | 2006 | 49 | 0.270 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2006 | 48 | 0.260 |
Why?
|
| 3,4-Methylenedioxyamphetamine | 1 | 2004 | 5 | 0.240 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2019 | 1239 | 0.240 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2006 | 70 | 0.240 |
Why?
|
| Metallothionein | 1 | 2004 | 13 | 0.240 |
Why?
|
| Serotonin | 1 | 2006 | 221 | 0.240 |
Why?
|
| Quality of Life | 1 | 2012 | 1662 | 0.230 |
Why?
|
| Cocaine | 1 | 2004 | 76 | 0.230 |
Why?
|
| Cross-Sectional Studies | 4 | 2020 | 1706 | 0.220 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 6777 | 0.220 |
Why?
|
| Striatonigral Degeneration | 1 | 2022 | 1 | 0.210 |
Why?
|
| Olivopontocerebellar Atrophies | 1 | 2022 | 6 | 0.210 |
Why?
|
| Membrane Transport Proteins | 2 | 2002 | 169 | 0.210 |
Why?
|
| Cerebral Cortex | 1 | 2016 | 589 | 0.210 |
Why?
|
| Comorbidity | 2 | 2021 | 948 | 0.200 |
Why?
|
| Corpus Striatum | 2 | 2016 | 87 | 0.190 |
Why?
|
| Spain | 1 | 2020 | 32 | 0.190 |
Why?
|
| France | 1 | 2020 | 48 | 0.190 |
Why?
|
| Intracellular Fluid | 1 | 2000 | 34 | 0.190 |
Why?
|
| Italy | 1 | 2020 | 107 | 0.180 |
Why?
|
| Blotting, Northern | 5 | 2004 | 258 | 0.180 |
Why?
|
| United States | 6 | 2024 | 6955 | 0.180 |
Why?
|
| Electric Countershock | 1 | 2020 | 53 | 0.180 |
Why?
|
| Body Temperature | 1 | 2000 | 124 | 0.180 |
Why?
|
| Disulfiram | 1 | 2020 | 8 | 0.180 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2019 | 302 | 0.180 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2020 | 47 | 0.170 |
Why?
|
| Copper | 1 | 2020 | 77 | 0.170 |
Why?
|
| Neurites | 1 | 2019 | 36 | 0.170 |
Why?
|
| Arginine | 1 | 2020 | 138 | 0.170 |
Why?
|
| Interferons | 1 | 2020 | 124 | 0.170 |
Why?
|
| Tauopathies | 1 | 2019 | 14 | 0.170 |
Why?
|
| Dopamine Agents | 1 | 2019 | 28 | 0.170 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 97 | 0.170 |
Why?
|
| Down-Regulation | 4 | 2006 | 519 | 0.160 |
Why?
|
| Catechol O-Methyltransferase Inhibitors | 1 | 1998 | 9 | 0.160 |
Why?
|
| Models, Animal | 1 | 2019 | 276 | 0.160 |
Why?
|
| Alternative Splicing | 1 | 2020 | 210 | 0.160 |
Why?
|
| RNA Splicing | 1 | 2020 | 152 | 0.160 |
Why?
|
| Nanoparticles | 1 | 2020 | 164 | 0.160 |
Why?
|
| Estrogens | 1 | 1999 | 201 | 0.160 |
Why?
|
| Dopamine Uptake Inhibitors | 3 | 2004 | 44 | 0.160 |
Why?
|
| Formamides | 1 | 1997 | 2 | 0.150 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1997 | 28 | 0.150 |
Why?
|
| Ethidium | 1 | 1997 | 13 | 0.150 |
Why?
|
| Time Factors | 3 | 2018 | 5320 | 0.150 |
Why?
|
| Cerebellum | 1 | 2019 | 249 | 0.150 |
Why?
|
| Cohort Studies | 5 | 2024 | 2863 | 0.150 |
Why?
|
| Consensus | 1 | 2019 | 356 | 0.150 |
Why?
|
| Antidepressive Agents | 1 | 1998 | 111 | 0.150 |
Why?
|
| Cisplatin | 1 | 2020 | 617 | 0.150 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2005 | 695 | 0.150 |
Why?
|
| Valine | 1 | 1997 | 62 | 0.140 |
Why?
|
| Cross-Over Studies | 1 | 2018 | 389 | 0.140 |
Why?
|
| Methionine | 1 | 1997 | 65 | 0.140 |
Why?
|
| Carrier Proteins | 1 | 2000 | 681 | 0.140 |
Why?
|
| Torticollis | 1 | 2016 | 11 | 0.140 |
Why?
|
| Positron-Emission Tomography | 2 | 2016 | 336 | 0.140 |
Why?
|
| Saliva | 1 | 2017 | 123 | 0.140 |
Why?
|
| Trinucleotide Repeats | 1 | 2016 | 32 | 0.140 |
Why?
|
| MicroRNAs | 1 | 2021 | 551 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 616 | 0.130 |
Why?
|
| Fluorescent Dyes | 1 | 1997 | 243 | 0.130 |
Why?
|
| Gene Expression Regulation | 2 | 2002 | 1975 | 0.130 |
Why?
|
| Transcription, Genetic | 2 | 2001 | 1157 | 0.130 |
Why?
|
| Neoplasms | 2 | 2021 | 3035 | 0.130 |
Why?
|
| Levodopa | 1 | 2015 | 36 | 0.130 |
Why?
|
| Calcium Channels | 1 | 2016 | 182 | 0.130 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 645 | 0.130 |
Why?
|
| Barium Sulfate | 1 | 2014 | 43 | 0.120 |
Why?
|
| Animals | 12 | 2020 | 27317 | 0.120 |
Why?
|
| Paraneoplastic Cerebellar Degeneration | 1 | 2014 | 1 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 967 | 0.110 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 3 | 2002 | 12 | 0.110 |
Why?
|
| Polymorphism, Genetic | 1 | 1997 | 824 | 0.110 |
Why?
|
| Myoclonus | 1 | 2013 | 16 | 0.110 |
Why?
|
| Cholinergic Antagonists | 1 | 2013 | 27 | 0.110 |
Why?
|
| Hypokinesia | 1 | 2012 | 3 | 0.110 |
Why?
|
| Mice | 7 | 2020 | 11737 | 0.100 |
Why?
|
| Amyloid beta-Peptides | 2 | 2017 | 212 | 0.100 |
Why?
|
| Electron Transport Complex IV | 2 | 2002 | 49 | 0.100 |
Why?
|
| Hemorrhage | 1 | 2014 | 278 | 0.100 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1855 | 0.100 |
Why?
|
| Peptide Fragments | 2 | 2017 | 463 | 0.100 |
Why?
|
| Atrophy | 2 | 2016 | 119 | 0.100 |
Why?
|
| Electrodes, Implanted | 1 | 2012 | 177 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2024 | 9003 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2006 | 1237 | 0.090 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1067 | 0.090 |
Why?
|
| alpha-Synuclein | 2 | 2022 | 19 | 0.090 |
Why?
|
| Prognosis | 2 | 2018 | 3773 | 0.090 |
Why?
|
| Austria | 2 | 2019 | 16 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 2552 | 0.080 |
Why?
|
| RNA, Messenger | 3 | 2004 | 2011 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2018 | 4273 | 0.080 |
Why?
|
| Rats | 3 | 2006 | 4040 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 2411 | 0.080 |
Why?
|
| Central Nervous System Agents | 1 | 2017 | 15 | 0.080 |
Why?
|
| Syndrome | 1 | 2018 | 449 | 0.070 |
Why?
|
| Central Nervous System | 1 | 1998 | 153 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 3443 | 0.070 |
Why?
|
| Australia | 1 | 2017 | 101 | 0.070 |
Why?
|
| Canada | 1 | 2017 | 208 | 0.070 |
Why?
|
| p-Chloroamphetamine | 1 | 2006 | 1 | 0.070 |
Why?
|
| 5,7-Dihydroxytryptamine | 1 | 2006 | 1 | 0.070 |
Why?
|
| Tryptophan Hydroxylase | 1 | 2006 | 11 | 0.070 |
Why?
|
| Fenfluramine | 1 | 2006 | 20 | 0.070 |
Why?
|
| Serotonin Agents | 1 | 2006 | 12 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2020 | 2552 | 0.070 |
Why?
|
| Europe | 1 | 2017 | 321 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 306 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 3000 | 0.070 |
Why?
|
| Molecular Sequence Data | 3 | 2001 | 3027 | 0.060 |
Why?
|
| Adult | 4 | 2024 | 26507 | 0.060 |
Why?
|
| Retinitis Pigmentosa | 1 | 2005 | 35 | 0.060 |
Why?
|
| Models, Neurological | 1 | 2018 | 409 | 0.060 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 114 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2017 | 1130 | 0.060 |
Why?
|
| Axons | 1 | 2006 | 180 | 0.060 |
Why?
|
| 4-Aminopyridine | 1 | 2024 | 35 | 0.060 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 2024 | 23 | 0.060 |
Why?
|
| Amphetamine | 1 | 2005 | 101 | 0.060 |
Why?
|
| Base Sequence | 2 | 1999 | 2327 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 2752 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2005 | 184 | 0.060 |
Why?
|
| Fibroblast Growth Factors | 1 | 2024 | 82 | 0.060 |
Why?
|
| Mesencephalon | 2 | 2001 | 64 | 0.060 |
Why?
|
| Purkinje Cells | 1 | 2024 | 84 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2020 | 1650 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2004 | 100 | 0.060 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2005 | 188 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 3 | 2003 | 956 | 0.050 |
Why?
|
| Estradiol | 1 | 2003 | 250 | 0.050 |
Why?
|
| Mental Disorders | 1 | 2017 | 412 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2016 | 850 | 0.050 |
Why?
|
| Autopsy | 1 | 2022 | 122 | 0.050 |
Why?
|
| HeLa Cells | 2 | 2003 | 511 | 0.050 |
Why?
|
| Membrane Transport Modulators | 1 | 2002 | 2 | 0.050 |
Why?
|
| Synaptosomes | 1 | 2002 | 10 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2003 | 269 | 0.050 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2002 | 16 | 0.050 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2002 | 35 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2657 | 0.050 |
Why?
|
| Young Adult | 1 | 2014 | 6288 | 0.050 |
Why?
|
| Protein Subunits | 1 | 2002 | 123 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 172 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2002 | 293 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 1796 | 0.050 |
Why?
|
| Gene Library | 1 | 2001 | 133 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 599 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 313 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2022 | 172 | 0.050 |
Why?
|
| Xenobiotics | 1 | 2001 | 7 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 2 | 1998 | 921 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2022 | 268 | 0.050 |
Why?
|
| Hypothermia, Induced | 1 | 2002 | 82 | 0.050 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2005 | 661 | 0.050 |
Why?
|
| 1-Methyl-4-phenylpyridinium | 1 | 2000 | 12 | 0.050 |
Why?
|
| Dioxygenases | 1 | 2001 | 76 | 0.050 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2022 | 491 | 0.050 |
Why?
|
| Transcytosis | 1 | 2020 | 3 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 2335 | 0.040 |
Why?
|
| Nanomedicine | 1 | 2020 | 14 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 57 | 0.040 |
Why?
|
| Oxides | 1 | 2020 | 43 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 1940 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2005 | 1429 | 0.040 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2019 | 4 | 0.040 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 1999 | 35 | 0.040 |
Why?
|
| Anisotropy | 1 | 2019 | 63 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2004 | 1990 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 3657 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2020 | 306 | 0.040 |
Why?
|
| COS Cells | 1 | 1999 | 167 | 0.040 |
Why?
|
| Temperature | 1 | 2000 | 400 | 0.040 |
Why?
|
| Nuclear Proteins | 2 | 2003 | 726 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 1999 | 275 | 0.040 |
Why?
|
| Circadian Rhythm | 1 | 2021 | 305 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 179 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 470 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 1999 | 646 | 0.040 |
Why?
|
| beta Catenin | 1 | 2020 | 266 | 0.040 |
Why?
|
| Sensation Disorders | 1 | 2017 | 24 | 0.040 |
Why?
|
| Postural Balance | 1 | 2017 | 45 | 0.040 |
Why?
|
| Protein Denaturation | 1 | 1997 | 106 | 0.040 |
Why?
|
| Cell Survival | 1 | 2020 | 982 | 0.040 |
Why?
|
| Staining and Labeling | 1 | 1997 | 168 | 0.040 |
Why?
|
| Neuroblastoma | 1 | 2000 | 394 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 216 | 0.030 |
Why?
|
| DNA Primers | 1 | 1997 | 543 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 459 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 1999 | 866 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 761 | 0.030 |
Why?
|
| Biological Specimen Banks | 1 | 2016 | 65 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2000 | 2880 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1997 | 412 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2022 | 1670 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2022 | 1652 | 0.030 |
Why?
|
| Alleles | 1 | 1997 | 1135 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2020 | 3373 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 1363 | 0.030 |
Why?
|
| Benztropine | 1 | 2013 | 4 | 0.030 |
Why?
|
| Apoptosis | 1 | 2020 | 1716 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 1999 | 1241 | 0.030 |
Why?
|
| Phenotype | 1 | 2019 | 2439 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 142 | 0.030 |
Why?
|
| RNA Probes | 1 | 1998 | 16 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2013 | 749 | 0.020 |
Why?
|
| Organ Specificity | 1 | 1998 | 272 | 0.020 |
Why?
|
| Exons | 1 | 1998 | 451 | 0.020 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 6 | 1 | 2005 | 1 | 0.020 |
Why?
|
| Rod Cell Outer Segment | 1 | 2005 | 2 | 0.020 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2005 | 25 | 0.020 |
Why?
|
| Saimiri | 1 | 2005 | 50 | 0.020 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2005 | 44 | 0.020 |
Why?
|
| Papio | 1 | 2005 | 82 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2005 | 231 | 0.020 |
Why?
|
| Eye Proteins | 1 | 2005 | 128 | 0.010 |
Why?
|
| Immunochemistry | 1 | 2003 | 16 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2003 | 111 | 0.010 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2003 | 73 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2003 | 130 | 0.010 |
Why?
|
| Response Elements | 1 | 2003 | 65 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2005 | 443 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 794 | 0.010 |
Why?
|
| Genes, Synthetic | 1 | 2001 | 7 | 0.010 |
Why?
|
| Lac Operon | 1 | 2001 | 47 | 0.010 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2001 | 44 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2001 | 88 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2005 | 556 | 0.010 |
Why?
|
| Cysteine Dioxygenase | 1 | 2001 | 1 | 0.010 |
Why?
|
| Nicotinamide N-Methyltransferase | 1 | 2001 | 6 | 0.010 |
Why?
|
| Oxygenases | 1 | 2001 | 13 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2001 | 392 | 0.010 |
Why?
|
| Methyltransferases | 1 | 2001 | 192 | 0.010 |
Why?
|
| DNA | 1 | 2003 | 1307 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2001 | 1574 | 0.010 |
Why?
|
| Mutation | 1 | 2005 | 4132 | 0.010 |
Why?
|